CHILDREN'S ELIXSURE (ibuprofen) by Moberg Pharma is cyclooxygenase inhibitors [moa]. First approved in 2004.
Drug data last refreshed 1h ago · AI intelligence enriched 1mo ago
Children's Elixsure is an oral ibuprofen suspension approved for pediatric use, indicated for fever reduction and pain relief in children. It works by inhibiting cyclooxygenase enzymes to reduce prostaglandin production and inflammation. This OTC product serves as a foundational analgesic/antipyretic in the pediatric market.
Product approaching loss of exclusivity with moderate competitive pressure (30%); brand team likely focused on defensive positioning and cost management rather than expansion.
Cyclooxygenase Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension
Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain
Efficacy and Safety of S (+) - Ibuprofen in the Treatment of Mechanical Low Back Pain
Postoperative Analgesic Effects of Ibuprofen Versus Ketorolac in Patients Undergoing in Orthopedic Surgery
Ibuprofen Plus Acetaminophen for Enhanced Pain Reduction
Worked on CHILDREN'S ELIXSURE at Moberg Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Children's Elixsure offers limited growth opportunity as the product approaches loss of exclusivity with no active pipeline expansion. Career roles focus on cost management, regulatory compliance, and supply chain rather than innovation, making this a consolidation or transition assignment rather than a growth platform.